Clinical Trial Update: Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of a Wee-1 inhibitor (AZD1775/MK-1775) with carboplatin in p53-mutated, refractory/resistant epithelial ovarian cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• AZD1775 (Adavosertib)
• CARBOPLATIN (Carboplatin)
• MK-1775 (adavosertib)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: COMPLETED